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Abstract 
Background: Elevated levels of fibrinogen may contribute to a prothrombotic state. Cross-sectional studies suggest 
fibrinogen possibly linked with MetS/its components, while results of cohort studies remain controversial. Thus, this 
study was designed to identify the association of plasma fibrinogen with metabolic syndrome (MetS) and further to 
clarify the role of fibrinogen in the development of MetS.
Methods: A large-scale prospective cohort study was conducted in routine health check-up population. 6209 
participants free of MetS at baseline were included in the original cohort, with annually routine health check-up for 
incident MetS from 2005 to 2011. Then, 4 pre-MetS sub-cohorts, with overweight, hypertension, hyperglycemia and 
dyslipidemia at baseline respectively, were also created from the original cohort. Various strategies of Cox model 
analysis were performed for attempting to confirm the role of fibrinogen in the development of MetS.
Results: Total MetS incidence density was 75.58 per 1000 person-years. Cox regression analysis by adjusting for 
potential confounders as well as four MetS components showed a significant effect of fibrinogen on MetS just in 
female, with risk ratio (RR) (95 % CI) of 1.48 (1.02, 2.13) for Q4 vs. Q1. Further analysis in the 4 pre-MetS female sub-
cohorts revealed this significant effect only in overweight sub-cohort, with RR (95 % CI) of 1.97 (1.20, 3.23), but no 
significant interaction of overweight with fibrinogen on MetS was revealed in original female cohort. Then, stratifica-
tion analysis among the 4 sub-groups of fibrinogen quartiles showed that effects of overweight on MetS were differ-
ent among the 4 sub-groups of fibrinogen quartiles, with RR of 2.98 for Q1, 4.40 for Q2, 3.93 for Q3, and 4.82 for Q4 
respectively.
Conclusions: Fibrinogen was associated with MetS just in overweight sub-cohort of female individuals, and fibrino-
gen might be a potential modifier in the pathway from overweight to MetS.
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Background
Metabolic syndrome (MetS), defined by clustering of 
overweight (obesity), elevated blood pressure, impaired 
glucose metabolism, dyslipidemia and typically 
characterized by insulin resistance, has become one of 
the major public health challenges worldwide [1–4]. 
Although the clinical value of MetS has controversy, 
there is agreement that clustering of risk factors pre-
dicts an increased risk of developing cardiovascular 
disease and helps identifying individuals at high risk 
of both type 2 diabetes and CVD [1, 5–7]. Fibrinogen, 
a key plasma protein synthesized in the liver, plays an 
important role in coagulation, plasma viscosity and 
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erythrocyte aggregation [8]. Thus, elevated levels of 
fibrinogen contribute to a prothrombotic state, and may 
play an important role in the development of MetS [9, 
10].
Epidemiologically, several cross-sectional studies 
had suggested that fibrinogen was possibly linked with 
MetS/its components [11–17]. Specifically, a cross-sec-
tional study in British birth cohort population showed 
a stronger correlation in females than in males, indi-
cating the differences between genders [14]. While, a 
cohort study in Turkish adults reported a reverse conclu-
sion with significant association in males rather than in 
females [18]. Furthermore, another prospective cohort 
study in Framingham offspring study attempted to iden-
tify the association, but found no relationship between 
them [19]. Therefore, considering these controversial 
results, it was of great value to identify the association of 
fibrinogen with MetS, and further to clarify what role of 
fibrinogen played in the development of MetS.
To achieve above purposes, we conducted a large-
scale cohort study in urban Han Chinese population. 
The original cohort was firstly constructed from routine 
health check-up population from 2005 to 2011without 
MetS at baseline. Then, 4 pre-MetS sub-cohorts (over-
weight, dyslipidemia, hypertension and hyperglycemia), 
were also created from the original cohort, with all over-
weight, dyslipidemia, hypertension and hyperglycemia 
subjects at baseline included respectively. Various strate-
gies of Cox model analysis were performed for attempt-
ing to confirm the role of fibrinogen in the development 
of MetS.
Methods
Study population and cohort design
The cohort study was conducted in routine health check-
up population at Center for Health Management of Shan-
dong Provincial Qianfoshan Hospital and Shandong 
Provincial Hospital. The original cohort was constructed 
from this routine health check-up population from 2005 
to 2011, and its framework was showed in Additional 
file 1: Figure S1. A total of 6209 participants free of MetS 
and other cardiovascular diseases were included in this 
cohort, to follow up for MetS with an annually regular 
clinical and laboratory examination. All subjects were 
more than 40-year-old, with 3843 males and 2366 females 
respectively. If necessary, 4 pre-MetS sub-cohorts, with 
overweight, dyslipidemia, hypertension and hyperglyce-
mia at baseline included respectively, would be created 
for further exploring the role of fibrinogen in the devel-
opment of MetS. The study protocol was approved by 
ethics committee of School of Public Health, Shandong 
University. Written informed consent was obtained from 
all participants.
Measurements
At baseline, plasma fibrinogen was tested by Clauss 
method [20]. MetS related biomarkers, including sys-
tolic blood pressure, diastolic blood pressure, body mass 
index, fasting plasma glucose (FPG), total cholesterol, 
triglyceride, HDL-cholesterol, LDL-cholesterol, were 
measured annually with standard clinical and laboratory 
protocol for follow-up of MetS. Lifestyle factors, includ-
ing smoking, drinking, vegetarian diet and exercise, 
were also obtained using standardized questionnaire. 
According to self-report smoking condition, smoking 
was categorized into never, former and current smoker. 
Subjects who reported frequently drinking were defined 
as frequent drinker; all others were non-frequent drinker. 
Subjects who took plant-based foods (mainly plant, but 
also took some meat) were defined as vegetarian; all oth-
ers were non-vegetarian. Subjects who took more than 5 
times 30 min of moderate activity per week or more than 
3 times 20 min of vigorous activity per week, or equiva-
lent were defined as regular exerciser; all others were 
non-regular exerciser.
Diagnosis of MetS
The MetS was diagnosed using criteria of Chinese medi-
cal association diabetes branch (CDS) [21], defined as 
meeting three or more of the following disorders: (1) 
overweight or overweight (BMI ≥ 25.0 kg/M2); (2) hyper-
tension (SBP ≥  140  mmHg, DBP ≥  90  mmHg or diag-
nosed before); (3) hyperglycemia (FPG  ≥  6.1  mmol/L 
or 2  h Postmeal Glucose ≥7.8  mmol/L, or diag-
nosed before); (4) dyslipidemia (TG  ≥  1.7  mmol/L, or 
HDL < 0.9 mmol/L in male and <1.0 mmol/L in female).
Statistical analysis
To account for missing values of covariates, multiple 
imputations were performed, and the Markov chain 
Monte Carlo (MCMC) method was chosen according 
to MI Procedure of SAS [22]. Most variables had less 
than 2 % missing observations before imputation except 
smoking, drinking, diet and physical activity having less 
than 10 % missing values.
Continuous variables were presented by mean (stand-
ard deviation) and categorical variables were summa-
rized as percentages. The fibrinogen level, originally 
continuous, was categorized into four quartiles (Q1–
Q4), with P25, P50 and P75 as cut-off values. Partici-
pants with and without incident MetS during follow-up 
was compared using t test for continuous variables, and 
Chi square test for categorical variables. Chi square 
trend test was used to detect the trend of MetS inci-
dence with increasing of fibrinogen from Q1 to Q4. Cox 
proportional hazards model was further used to detect 
the association of fibrinogen with MetS after adjusting 
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potential confounders, including age, smoking, drinking, 
vegetarian diet and exercise, as well as baseline status of 
overweight, dyslipidemia, hypertension and hyperglyce-
mia. Further analysis was conducted in four sub-cohorts 
(overweight, dyslipidemia, hypertension and hypergly-
cemia). Specifically, to detect whether fibrinogen was 
interacted with overweight on MetS, fibrinogen × over-
weight was put into the Cox model with adjusting other 
potential confounders in original female cohort; and to 
further illustrate the role of fibrinogen in the pathway 
from overweight to MetS, stratification analysis with 
Cox model was conducted in the 4 sub-groups of fibrin-
ogen quartiles. All data analysis was performed using 
SAS version 9.2 (SAS Institute, Inc., Cary, NC, USA). 
A two-sided P  <  0.05 was considered to be statistically 
significant.
Results
In this cohort, among 6209 (3843 males and 2366 
females) participants free of MetS at baseline, 1175 MetS 
(853 males and 322 females) were observed during the 
5-year follow-up, and the total incidence density was up 
to 75.58 per 1000 person-years (1175/15547), with 89.85 
(853/9494) and 53.20 per 1000 person-years (322/6053) 
for male and female respectively.
Table  1 showed the baseline fibrinogen and MetS 
related factors in MetS and non-MetS within total, male 
and female groups. Obviously, fibrinogen level was sig-
nificantly higher in MetS than in non-MetS for entire 
cohort (t value = −4.39, P < 0.05) and for both male (t 
value  =  −2.62, P  <  0.05) and female (t value  =  −5.98, 
P  <  0.05), and significant differences of other factors, 
except smoking in male and smoking, drinking, vegetar-
ian diet in female, were also detected between MetS and 
non-MetS in the two groups. In addition, baseline char-
acteristics of participants grouped by fibrinogen quartiles 
were also showed in Additional file 2: Table S1.
Figure 1 illustrated the incidence of MetS by quartiles 
of fibrinogen in the whole participants (a), as well as in 
the overweight (b), dyslipidemia (c), hypertension (d), 
and hyperglycemia (e) sub-cohorts for male and female 
group respectively. For the whole participants, an obvi-
ous increasing trend of MetS incidence with fibrinogen 
was observed in both male (chisq = −3.2073, P = 0.0007) 
and female (chisq = −7.2832, P < 0.0001). However, the 
increasing slope was much stronger in female than in 
male, especially in overweight and dyslipidemia sub-
cohorts. Specifically, in the four sub-cohorts of female, 
increasing trends of MetS incidence with fibrino-
gen were observed in overweight (chisq  =  −4.5632, 
P < 0.0001), dyslipidemia (chisq = −3.0322, P = 0.0012), 
and in hypertension (chisq  =  −1.8330, P  =  0.0334), 
while no increasing trend revealed in hyperglycemia 
(chisq = −0.7136, P = 0.2377). In contrary, no increasing 
trends were found in the four male sub-cohorts.
Table  2 illustrated the RR (95  % CIs) from Cox mod-
els with different adjusting factors in the entire cohort as 
well as in male and female respectively. In female, model 
1 and model 2 suggested an obviously significant dose–
response effect of fibrinogen on MetS with Q1 (fibrino-
gen ≤2.92 g/L) as reference level, with P value for trend of 
0.0011 and 0.0498 for model 1 and model 2 respectively. 
By adjusting age, smoking, drinking, vegetarian diet 
and exercise (model 1), the RR (95  % CI) of fibrinogen 
on MetS (Q4 vs. Q1) was 1.84 (1.27, 2.66). After further 
adjusting the four MetS components (overweight, dyslip-
idemia, hypertension, hyperglycemia) in model 2, the RR 
became 1.48 (1.02, 2.13), indicating that fibrinogen might 
be an independent risk factor of MetS in females. How-
ever, similar trend was not observed in male as well as in 
the entire cohort.
As fibrinogen associated with MetS just in female, 4 
pre-MetS female sub-cohorts, with overweight (n = 717), 
dyslipidemia (n  =  483), hypertension (n  =  511) and 
hyperglycemia (n = 115) at baseline, was created for fur-
ther exploring the role of fibrinogen in the development 
of MetS. Table  3 showed their RR (95  % CI) from Cox 
models with adjusting other potential confounders. Obvi-
ously, significant association of fibrinogen with MetS was 
only detected in the overweight sub-cohort, with RR of 
1.97(95 % CI 1.20, 3.23) for Q4 vs. Q1.
As fibrinogen was associated with MetS just in over-
weight sub-cohort of females, the interaction of fibrino-
gen and overweight should be detected in the original 
female cohort. After adjusting age, smoking, drinking, 
vegetarian diet, exercise, hypertension, hyperglycemia, 
dyslipidemia, no statistically significant interaction of 
overweight and fibrinogen on MetS was revealed, and 
the main effect of overweight was still statistically signifi-
cant whilst fibrinogen non-significant (Seeing model 3 in 
Table 2), suggesting that fibrinogen might be a modifier 
in the pathway from overweight to MetS.
To illustrate whether fibrinogen was a modifier in the 
pathway from overweight to MetS, stratification analy-
sis with Cox model was conducted in the 4 sub-groups 
of fibrinogen quartiles. As showed in Table  4, effects of 
overweight on MetS were quite different among the four 
sub-groups, with RR of 2.98 for Q1, 4.40 for Q2, 3.93 for 
Q3, and 4.82 for Q4 respectively, indicating that fibrino-
gen was a potential modifier in the pathway from over-
weight to MetS.
Discussion
In this cohort study, the total MetS incidence density 
of 75.58 per 1000 person-years observed in this spe-
cific urban Han Chinese population during the 5-year 
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follow-up, with 89.85 and 53.20 for male and female 
respectively, and statistically significant difference of 
fibrinogen level between MetS and non-MetS groups was 
further detected in the two gender groups (Table 1). Sim-
ilar gender difference of MetS was also reported in British 
[14], Pakistan [23], Frinks cohort [24], and TLGS cohort 
[25] population. In the contrary, female dominance of 
MetS was also reported in several populations [26–29]. 
The heterogeneity of MetS between genders among dif-
ferent population might be due to their different risk fac-
tor exposure pattern, suggesting that gender stratification 
analysis should be considered for further detecting the 
association of fibrinogen with MetS.
A much stronger increasing trend of MetS incidence 
with fibrinogen quartiles was observed in female rather 
than in male (Fig.  1a). Specifically, similar obviously 
increasing trends were also detected in overweight, 
dyslipidemia, and hypertension female sub-cohorts 
(Fig. 1b–d). Further Cox regression analysis by adjusting 
for baseline smoking, exercise and the four MetS com-
ponents showed an obviously significant association of 
fibrinogen with MetS in female, but no association was 
detected in male (Table 2). Similar gender difference was 
also reported in British population by cross-sectional 
study in British birth cohort [14] while reverse trend was 
claimed in Turkish cohort study [18]. These gender dif-
ferences in different population remained a controversial 
issue for further investigations. One possible explanation 
might be that in the development of MetS, fibrinogen, 
as a proinflammatory factor, acted largely addictively to 
insulin resistance in female, whereas such effect might 
not exist in male [30–32].
Table 1 Characteristics comparison between  participants with  and without  incident MetS during  follow-up in  total, 
males and females
Characteristics Total Males Females
Non-MetS 
(n = 5034)
MetS P value Non-MetS 
(n = 2990)
MetS P value Non-MetS 
(n = 2044)
MetS (n = 322) P value
(n = 1175) (n = 853)
Fibrinogen (g/L) 3.29 ± 0.81 3.4 ± 0.83 <0.0001 3.21 ± 0.8 3.30 ± 0.82 0.0088 3.39 ± 0.81 3.68 ± 0.81 <0.0001
Age 51.55 ± 10.2 55.29 ± 11.2 <0.0001 52.03 ± 10.57 53.98 ± 11.00 <0.0001 50.84 ± 9.60 58.78 ± 10.99 <0.0001
Male (%) 2990 (59.4) 853 (72.6) <0.0001
Female (%) 2044 (40.6) 322 (27.4) <0.0001
Overweight (%) 1853 (36.81) 816 (69.45) <0.0001 1334 (44.62) 618 (72.45) <0.0001 519 (25.39) 198 (61.49) <0.0001
Dyslipidemia (%) 1352 (26.86) 444 (37.79) <0.0001 969 (32.41) 344 (40.33) <0.0001 383 (18.74) 100 (31.06) <0.0001
Hypertension (%) 977 (19.41) 495 (42.13) <0.0001 629 (21.04) 332 (38.92) <0.0001 348 (17.03) 163 (50.62) <0.0001
Hyperglycemia 
(%)
230 (4.57) 136 (11.57) <0.0001 155 (5.18) 96 (11.25) <0.0001 75 (3.67) 40 (12.42) <0.0001
Former smoker 164 (3.26) 50 (4.26) 0.008 122 (4.08) 48 (5.63) 0.1125 42 (2.05) 2 (0.62) 0.1893
Current smoker 
(%)
1430 (28.41) 375 (31.91) 0.008 1331 (44.52) 361 (42.32) 0.1125 99 (4.84) 14 (4.35) 0.1893
Frequent drinker 
(%)
1189 (23.62) 354 (30.13) <0.0001 1070 (35.79) 339 (39.74) 0.0344 119 (5.82) 15 (4.66) 0.4012
Vegetarian (%) 1535 (30.49) 296 (25.19) 0.0003 745 (24.92) 177 (20.75) 0.012 790 (38.65) 119 (36.96) 0.5615
Regular exercise 
(%)
2860 (56.81) 583 (49.62) <0.0001 1599 (53.48) 418 (49.00) 0.021 1261 (61.69) 165 (51.24) 0.0004
BMI (kg/m2) 24.18 ± 4.55 26.5 ± 2.74 <0.0001 24.80 ± 2.70 26.67 ± 2.61 <0.0001 23.27 ± 6.23 26.04 ± 3.01 <0.0001
Systolic BP 
(mmHg)
122.75 ± 17.71 134.35 ± 17.8 <0.0001 124.97 ± 16.84 133.74 ± 17.16 <0.0001 119.49 ± 18.43 135.96 ± 19.3 <0.0001
Diastolic BP 
(mmHg)
73.08 ± 10.48 79.32 ± 10.57 <0.0001 74.77 ± 10.25 79.91 ± 10.26 <0.0001 70.6 ± 10.31 77.77 ± 11.21 <0.0001
FPG (mg/dl) 5.05 ± 0.75 5.5 ± 1.07 <0.0001 5.09 ± 0.76 5.48 ± 1.05 <0.0001 4.98 ± 0.73 5.54 ± 1.11 <0.0001
Total cholesterol 
(mg/dl)
5.19 ± 0.92 5.36 ± 1 <0.0001 5.14 ± 0.88 5.23 ± 0.94 0.0103 5.26 ± 0.98 5.71 ± 1.07 <0.0001
Triglyceride (mg/
dl)
1.37 ± 0.99 1.79 ± 1.33 <0.0001 1.53 ± 1.08 1.85 ± 1.46 <0.0001 1.13 ± 0.78 1.62 ± 0.92 <0.0001
HDL-cholesterol 
(mg/dl)
1.35 ± 0.32 1.26 ± 0.29 <0.0001 1.26 ± 0.28 1.23 ± 0.30 0.0012 1.47 ± 0.32 1.35 ± 0.26 <0.0001
LDL-cholesterol 
(mg/dl)
2.95 ± 0.71 3.11 ± 0.72 <0.0001 3.00 ± 0.69 3.06 ± 0.71 0.0208 2.88 ± 0.73 3.25 ± 0.73 <0.0001
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At present study, fibrinogen associated with MetS 
just in female reminded us to focus on the association 
analysis in overweight, dyslipidemia, hypertension and 
hyperglycemia female subjects respectively. As showed 
in Table  3, significantly positive association was only 
revealed in overweight sub-cohort. This indicated that 
fibrinogen played a major role in the pathway from over-
weight to MetS for female. A perceptive review, about 
obesity, haemostasis and the fibrinolytic system [33], 
provided clues for hunting the role of fibrinogen in this 
pathway. The authors highlighted the pathway from insu-
lin resistance/hyperinsulinaemia to obesity to traditional 
MetS components (hypertension, hyperglycemia and 
dyslipidemia) and haemostatic/fibrinolytic disturbances, 
and finally to cardiovascular diseases; and further con-
cluded that fibrinogen, as a downstream component of 
the inflammatory cascade [34, 35] in the pathway, was 
increased in overweight (obese) subjects, and associated 
with insulin resistance. However, from this review, what 
role of fibrinogen played in the pathway of overweight 
to MetS still remained unclear. For fibrinogen positively 
associated with MetS just in female, it might be partly 
explained by the effect of estrogen. A cross-sectional 
study [36] reported that fibrinogen was positively corre-
lated with endogenous estrone, while a cohort study [37] 
further reported that estradiol was positively associated 
of plasma fibrinogen, especially in subjects who were 
overweight.
To detect whether fibrinogen was interacted with over-
weight on MetS, fibrinogen*overweight was put into the 
Cox model with adjusting other potential confounders 
(Showed in model 3, Table  2). Unexpectedly, although 
the main effect of overweight still statistically signifi-
cant, no significant interaction of overweight*fibrinogen 
on MetS was revealed, and the main effect of fibrinogen 
became non-significant simultaneously. The results sug-
gested that fibrinogen might be a potential modifier in 
the pathway from overweight to MetS. This hypothesis 
was supported by our further stratification analysis in the 
4 sub-groups of fibrinogen quartiles with Cox model by 
adjusting other potential confounders. Because effects 
of overweight on MetS were quite different among the 
4 sub-groups of fibrinogen quartiles, with RR of 2.98 for 
Q1, 4.40 for Q2, 3.93 for Q3, and 4.82 for Q4 respectively 
(showed in Table 4). These suggested that female individ-
uals with overweight and elevated fibrinogen should pay 
more attention to their blood pressure, blood sugar and 
blood lipid for early prevention of MetS.
In fact, the mechanism of fibrinogen in the development 
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Fig. 1 The incidence of MetS by quartiles of fibrinogen in whole participants (a) and in overweight (b), dyslipidemia (c), hypertension (d), and 
hyperglycemia (e) sub-cohorts in male and female. In whole participants (a), 853 of 3843 males and 322 of 2366 females developed MetS during 
follow-up; In overweight sub-cohort (b), 618 of 1952 males and 198 of 717 females developed MetS during follow-up; In dyslipidemia sub-cohort 
(c), 344 of 1313 males and 100 of 483 females developed MetS during follow-up; In hypertension sub-cohort (d), 332 of 961 males and 163 of 511 
females developed MetS during follow-up; In hyperglycemia sub-cohort (e), 96 of 251 males and of 115 females developed MetS during follow-up
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Table 2 Risk ratios (RR) and  their 95  % confidence intervals (CI) from  Cox model for  association of  fibrinogen on  MetS 
in male and female
For fibrinogen quartiles, in whole participates, Q1 was defined as fibrinogen ≤2.79 g/l, Q2 was defined as fibrinogen in 2.79–3.20 g/l, Q3 was defined as fibrinogen 
in 3.20–3.567 g/l, and Q4 was defined as fibrinogen >3.67 g/l; in male, Q1 was defined as fibrinogen ≤2.71 g/l, Q2 was defined as fibrinogen in 2.71–3.14 g/l, Q3 was 
defined as fibrinogen in 3.14–3.58 g/l, and Q4 was defined as fibrinogen >3.58 g/l; in female, Q1 was defined as fibrinogen ≤2.92 g/l, Q2 was defined as fibrinogen in 
2.92–3.32 g/l, Q3 was defined as fibrinogen in 3.32–3.81 g/l, and Q4 was defined as fibrinogen >3.81 g/l
Model 1. adjusted by baseline covariates of age, gender, smoking, alcohol, vegetarian diet, exercise
Model 2. adjusted by baseline covariates of age, gender, smoking, alcohol, vegetarian diet, exercise, overweight, hypertension, hyperglycemia, dyslipidemia
Model 3. adjusted by baseline covariates of age, gender, smoking, alcohol, vegetarian diet, exercise, overweight, hypertension, hyperglycemia, dyslipidemia, 
interaction of fibrinogen and overweight
Total (n = 6209) Male (n = 3637) Female (n = 2260)
Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 Model 3
Fibrinogen quartiles
 Q2 vs. Q1 1.12 (0.94,1.33) 1.03 (0.87,1.23) 1.09 (0.89,1.32) 1.00 (0.82,1.22) 1.43 (0.97,2.12) 1.33 (0.90,1.96) 1.04 (0.58,1.87)
 Q3 vs. Q1 1.19 (1.01,1.41) 1.01 (0.85,1.20) 1.11 (0.91,1.35) 0.92 (0.76,1.12) 1.66 (1.14,2.4) 1.45 (1.00,2.10) 1.22 (0.71,2.10)
 Q4 vs. Q1 1.39 (1.17,1.65) 1.15 (0.97,1.36) 1.22 (1,1.48) 1.05 (0.86,1.28) 1.84 (1.27,2.66) 1.48 (1.02,2.13) 1.03 (0.60,1.77)
P value for trend 0.0019 0.1925 0.0523 0.8046 0.0011 0.0498
Age 1.03 (1.02,1.03) 1.02 (1.01,1.02) 1.02 (1.01,1.02) 1.01 (1.00,1.02) 1.05 (1.04,1.06) 1.03 (1.02,1.04) 1.03 (1.02,1.04)
Female 0.65 (0.57,0.75) 0.89 (0.77,1.03)
Former smoking 1.06 (0.79,1.42) 1.22 (0.91,1.64) 1.18 (0.87,1.59) 1.32 (0.98,1.79) 0.39 (0.09,1.61) 0.45 (0.11,1.88) 0.46 (0.11,1.94)
Current smoking 0.95 (0.83,1.09) 0.99 (0.86,1.14) 0.93 (0.81,1.08) 0.98 (0.85,1.14) 0.87 (0.49,1.52) 0.96 (0.55,1.67) 0.96 (0.55,1.68)
Frequent drinker 1.34 (1.17,1.55) 1.19 (1.03,1.37) 1.3 (1.12,1.51) 1.18 (1.02,1.37) 0.99 (0.57,1.72) 0.96 (0.55,1.67) 0.95 (0.54,1.65)
Vegetarian 0.77 (0.68,0.89) 0.83 (0.72,0.95) 0.78 (0.65,0.92) 0.83 (0.70,0.99) 0.77 (0.61,0.97) 0.81 (0.64,1.02) 0.81 (0.64,1.02)
Regular exerciser 1.03 (0.92,1.16) 1.02 (0.91,1.15) 1.02 (0.89,1.17) 1.02 (0.89,1.17) 1.17 (0.93,1.46) 1.06 (0.84,1.32) 1.04 (0.83,1.31)
Overweight 3.60 (3.15,4.11) 3.29 (2.81,3.87) 4.11 (3.23,5.22) 2.76 (1.5,5.06)
Dyslipidemia 2.36 (2.06,2.71) 2.13 (1.81,2.50) 2.75 (2.11,3.57) 2.82 (2.16,3.67)
Hypertension 3.04 (2.64,3.5) 2.83 (2.39,3.35) 3.20 (2.46,4.18) 3.26 (2.49,4.25)
Hyperglycemia 3.48 (2.87,4.23) 3.26 (2.59,4.11) 3.85 (2.70,5.48) 3.95 (2.76,5.63)
Overweight*fibrinogen
 1*Q2 1.54 (0.70,3.38)
 1*Q3 1.37 (0.66,2.88)
 1*Q4 1.85 (0.90,3.80)
Table 3 Risk ratios (RR) and  their 95  % confidence intervals (CI) from  Cox model for  association of  fibrinogen on  MetS 
in female overweight, dyslipidemia, hypertension and hyperglycemia sub-cohorts
Overweight (n = 717) Dyslipidemia (n = 483) Hypertension (n = 511) Hyperglycemia 
(n = 115)
Fibrinogen quartiles
 Q2 vs. Q1 1.67 (0.98,2.84) 1.28 (0.65,2.54) 0.90 (0.50,1.62) 0.77 (0.24,2.51)
 Q3 vs. Q1 1.69 (1.02,2.81) 1.49 (0.78,2.84) 1.07 (0.63,1.84) 1.26 (0.46,3.43)
 Q4 vs. Q1 1.97 (1.20,3.23) 1.44 (0.75,2.76) 1.10 (0.65,1.85) 0.77 (0.30,1.97)
Age 1.03 (1.02,1.05) 1.04 (1.02,1.07) 1.02 (1.00,1.03) 1.03 (1.00,1.07)
Smoking 0.92 (0.63,1.35) 1.25 (0.75,2.07) 1.00 (0.67,1.47) 1.60 (0.71,3.59)
Frequent drinker 0.72 (0.33,1.58) 0.38 (0.11,1.39) 0.97 (0.48,1.97) 3.24 (0.69,15.1)
Vegetarian 0.78 (0.57,1.05) 0.98 (0.65,1.49) 0.82 (0.59,1.13) 0.76 (0.37,1.56)
Regular exerciser 0.77 (0.57,1.03) 0.82 (0.55,1.22) 1.08 (0.79,1.48) 1.02 (0.52,2.01)
Overweight 4.34 (2.52,7.47) 4.18 (2.63,6.66) 2.89 (1.07,7.83)
Dyslipidemia 2.59 (1.70,3.94) 3.26 (1.87,5.69) 1.64 (0.52,5.17)
Hypertension 2.94 (1.98,4.34) 3.49 (1.89,6.45) 2.22 (0.79,6.24)
Hyperglycemia 3.29 (1.75,6.18) 3.16 (1.25,7.98) 4.09 (2.11,7.95)
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that fibrinogen might promote individuals with over-
weight to develop into MetS. But their causal relation-
ship still remained uncertain. It is possible that fibrinogen 
might be an accompanying biomarker in the development 
of MetS from overweight. Therefore, further experimental 
researches should be conducted for confirming the role of 
fibrinogen in the development of MetS.
Selection bias and information bias were inevitable in 
this cohort study, due to its biased subjects from rou-
tine health check-up in this specific urban Han Chinese 
population, and relatively shorter follow-up period. In 
addition, for only BMI was used to measure overweight 
in health check-up setting, the diagnostic criteria of MetS 
was based on China Diabetes Federation, rather than 
international standard criteria. CRP and other inflamma-
tion biomarkers were not measured, so associations for 
additional biomarkers and adjustment for CRP could not 
be conducted in this study. Further unbiased investiga-
tions with long follow-up period should be conducted in 
general community population.
Conclusions
Plasma fibrinogen was associated with MetS just in over-
weight sub-cohort of female individuals, and it might be a 
potential modifier in the pathway from overweight to MetS.
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